Epidermal growth factor receptor (EGFR), also known as HER1 or ERBB1, is essential for the development and progression of various cancers, including colorectal, head and neck, gastric, non-small-cell lung, and PCa [135,136,137] Hence, EGFR seems a promising therapeutic target, with the development of specific anticancer drugs such as EGFR-tyrosine kinase inhibitors (TKI). Here, EGFR is linked to cancer.